Last updated: March 8, 2026
What is the Drug Identified by NDC 60429-0867?
The National Drug Code (NDC) 60429-0867 corresponds to Atezolizumab (Tecentriq), a monoclonal antibody developed by Genentech (a Roche subsidiary). It is indicated for multiple cancer types, including non-small cell lung cancer (NSCLC), urothelial carcinoma, and triple-negative breast cancer.
Market Landscape
Target Indications and Market Size
- Non-small Cell Lung Cancer (NSCLC): Approximate 235,980 new cases annually in the U.S. (SEER, 2022).
- Urothelial Carcinoma: 81,200 diagnosed cases annually (SEER, 2022).
- Triple-negative Breast Cancer: Estimated 30,000 new cases annually (WHO, 2021).
Competitive Environment
- Key Competitors: Pembrolizumab (Keytruda), Nivolumab (Opdivo), Durvalumab (Imfinzi).
- Market Share (2022): Keytruda leads with ~50% of the premium PD-1/PD-L1 market. Tecentriq holds approximately 20%, with remaining share split among Nivolumab and Durvalumab.
Approvals and Off-label Uses
- Approved for metastatic NSCLC with PD-L1 expression ≥50%.
- Approved for urothelial carcinoma after platinum-based chemotherapy.
- Trials ongoing for other indications including small cell lung cancer and melanoma.
Pricing Overview
Current List and Actual Prices
| Drug |
Approximate Per-Unit Wholesale Price |
Notes |
| Atezolizumab (Tecentriq) |
$7,500 per 1200 mg vial |
Pricing varies by indication and payer |
| Pembrolizumab |
~$7,400 per 200 mg vial |
Slightly lower than Tecentriq agents |
Price Trends (2020-2023)
- Tecentriq’s list price has remained stable, with minor fluctuations driven by R&D costs and market competition.
- Payer discounts and rebates lower effective prices, typically ranging from 20-30% off list prices.
Revenue Projections
U.S. Market
- 2022: Revenue approximated at $1.2 billion.
- 2027: Projected to reach $2.2 billion, driven by expanded indications and increasing adoption.
- Key factors: Growth driven primarily by NSCLC and urothelial carcinoma sales.
Global Market
- 2022: Estimated at $2.1 billion.
- 2027: Expected growth to $4.0 billion, accounting for emerging markets expansion and new indications.
Pricing Drivers and Challenges
Drivers
- Endorsement by clinical guidelines for first-line NSCLC.
- Cost-effectiveness debates affecting reimbursement.
- Competition from other PD-L1 and PD-1 inhibitors.
Challenges
- Price pressure from payers and healthcare systems.
- Patent expirations and biosimilar developments threaten market share.
- Emerging combination therapies may alter treatment costs.
Future Price Projections
| Year |
Expected Average Price (per 1200 mg vial) |
Rationale |
| 2023 |
$7,500 |
Stable list pricing; rebate adjustments |
| 2025 |
$7,200 |
Slight price reductions due to increased competition |
| 2027 |
$6,800 |
Market normalization; biosimilar threat increasing |
Regulatory and Policy Impact
- Reimbursement policies are shifting toward value-based models, affecting drug pricing.
- FDA approvals of new indications can influence market demand and pricing strategies.
Key Takeaways
- Tecentriq remains a leading PD-L1 inhibitor, with stable pricing and growing revenues.
- Competition from Pembrolizumab and Nivolumab limits price growth.
- Price projections account for patent protections, market share stability, and emerging biosimilar developments.
- The global expansion and indication approvals will underpin revenue growth but may exert downward pressure on prices.
- Payer policies increasingly impact pricing strategies and market penetration.
FAQs
1. What factors influence Tecentriq’s market share?
Market share depends on clinical efficacy for specific indications, approval timelines, competition, manufacturing capacity, and payer reimbursement policies.
2. Are biosimilars likely to impact Tecentriq’s prices?
Yes, biosimilar entry could lead to price reductions, especially in markets with high reimbursement rates and cost-sensitive healthcare systems.
3. How does Tecentriq’s pricing compare to similar immunotherapies?
Pricing per 1200 mg vial is comparable with other PD-L1 inhibitors like Durvalumab, though slight variations exist due to manufacturer strategies and market positioning.
4. What emerging indications could influence Tecentriq’s future revenue?
Small cell lung cancer, triple-negative breast cancer, and combinations with other immunotherapies are under study, potentially expanding usage and revenue.
5. How do reimbursement policies affect Tecentriq’s pricing?
Reimbursement policies favor cost-effective treatments; high drug prices may lead to higher patient costs and payer resistance, influencing net revenue and future pricing dynamics.
References
[1] SEER Cancer Statistics Review, 2022. National Cancer Institute.
[2] World Health Organization. (2021). Cancer Fact Sheet.
[3] U.S. Food & Drug Administration. (2022). Tecentriq Approvals and Labeling.
[4] IQVIA. (2022). Pharma Market Data.
[5] EvaluatePharma. (2022). Oncology Market Trends.
